Advertisement

International Journal of Hematology

, Volume 98, Issue 1, pp 74–88 | Cite as

Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology

  • Keizo HoribeEmail author
  • Akiko M. Saito
  • Tetsuya Takimoto
  • Masahiro Tsuchida
  • Atsushi Manabe
  • Midori Shima
  • Akira Ohara
  • Shuki Mizutani
Original Article

Abstract

Neither accurate incidence nor survival data for pediatric patients with hematological malignancies (HM) have been available in Japan to date. Incidence of patients under 20 years of age, who were diagnosed with HM from 2006 to 2010, and their two-year survival rate (2y-OS) were obtained from disease registry data maintained by the Japan Society of Pediatric Hematology (JSPH). A total of 5,287 cases of HM were identified during this period. Acute lymphoblastic leukemia (ALL, 46.6 %) showed the highest incidence, followed by acute myeloid leukemia (AML, 16.7 %), non-Hodgkin lymphoma (NHL, 11.9 %), and histiocytosis (11.8 %). ALL, AML and histiocytosis were common in younger patients aged 1–4, while NHL tended to occur more frequently in older patients aged 5–14. The 2y-OS of HM was 91.6 %, with that for the most common B-precursor ALL rising to 96.2 %. The 2y-OS for M3 AML, lymphoblastic-B-precursor or diffuse large B cell NHL, Hodgkin lymphoma, myeloproliferative disorders, and Langerhans cell histiocytosis was >95 %. There were no gender differences in prognosis, while infants (88.0 %) and adolescents aged 15–19 (90.6 %) tended toward a poorer prognosis. This is the first report to describe incidence and survival times from the nationwide JSPH disease registry. More precise data with longer follow-up is needed.

Keywords

Hematological malignancies Children Registry data Survival 

Notes

Acknowledgments

The survey on hematological malignancies incidence in Japan was conducted with contributions from the 187 institutions, described in Appendix 1. The authors thank deeply the members, especially Kaori Nagai, Kazumi Takeuchi, Maki Nishimura, and Midori Otomo of the Data Management Department of the NPO-OSCR, for their support in the management of the electronic or paper-based survey system and in the cleaning and tabulation of the registered data.

Conflict of interest

The authors have no financial relationship to declare.

References

  1. 1.
    The Research Program for the Treatment of Chronic Pediatric Diseases of Specified Categories: Department of Health Policy. Available from URL: http://www.nch.go.jp/policy/shoumann.htm. Accessed October, 2012.
  2. 2.
    Research group of the Treatment of Chronic Pediatric Diseases of Specified Categories. Available from URL: http://www.aiiku.or.jp/aiiku/mch/syoman/syo.html. Accessed October, 2012.
  3. 3.
    Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42(2):139–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: a trend or a chance? J Pediatr. 1997;130(4):557–60.PubMedCrossRefGoogle Scholar
  5. 5.
    The Committee of the Japan Children’s Cancer Registry. The Japan Children’s Cancer Registry: outline, results, and perspectives. In: Watanabe S, Tominaga S, Kakizoe T, editors. Cancer Treatment and survival. Tokyo: CRC Press; 1995.Google Scholar
  6. 6.
    Ajiki W, Hanai A, Tsukuma H, Hiyama T, Fujimoto I. Incidence of childhood cancer in Osaka, Japan, 1971–1988: reclassification of registered cases by Birch’s scheme using information on clinical diagnosis, histology and primary site. Jpn J Cancer Res. 1994;85(2):139–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):255–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. Leukemia. 2010;24(2):406–18.PubMedCrossRefGoogle Scholar
  10. 10.
    Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL–BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):345–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol. 2009;10(10):957–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009;21(1):1–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Disease Registry Committee for the Japanese Society of Pediatric Hematology. Annual Report of Nationwide Survey 2008. Jpn J Pediatr Hematol. 2009;23:213–9.Google Scholar
  16. 16.
    Disease Registry Committee for the Japanese Society of Pediatric Hematology. Annual Report of Nationwide Survey 2009. Jpn J Pediatr Hematol. 2010;24:182–9.Google Scholar
  17. 17.
    Disease Registry Committee for the Japanese Society of Pediatric Hematology, Diagnostic guidelines for hematological diseases. Jpn J Pediatr Hematol. 2009;21 Suppl 5/6:1–76.Google Scholar
  18. 18.
    Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev. 2003;29(1):31–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRefGoogle Scholar
  20. 20.
    Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36.PubMedCrossRefGoogle Scholar
  21. 21.
    Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol. 2012;159(3):259–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol. 1993;11(6):1046–54.PubMedGoogle Scholar
  23. 23.
    Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001;98(6):1714–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007–13.PubMedCrossRefGoogle Scholar
  26. 26.
    Imaizumi M, Tawa A, Hanada R, Tsuchida M, Tabuchi K, Kigasawa H, et al. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol. 2011;152(1):89–98.PubMedCrossRefGoogle Scholar
  27. 27.
    Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2007;25(34):5442–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003–06 from the Japan Association of Childhood Leukaemia Study. Br J Haematol. 2012;159(2):204–10.PubMedCrossRefGoogle Scholar
  29. 29.
    Koga Y, Kumagai M, Takimoto T, Mimaya J, Nakazawa A, Horibe K, et al. Retrospective analysis of 157 patients with pediatric Hodgkin lymphoma in Japan: investigation by four pediatric cancer study groups. Rinsho Ketsueki. 2012;53(4):443–9.PubMedGoogle Scholar
  30. 30.
    Manipadam MT, Nair S, Viswabandya A, Mathew L, Srivastava A, Chandy M. Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India. World J Pediatr. 2011;7(4):318–25.PubMedCrossRefGoogle Scholar
  31. 31.
    Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children’s Cancer Study Group. J Clin Pathol. 1997;50(2):128–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Spitz MR, Sider JG, Johnson CC, Butler JJ, Pollack ES, Newell GR. Ethnic patterns of Hodgkin’s disease incidence among children and adolescents in the United States, 1973–82. J Natl Cancer Inst. 1986;76(2):235–9.PubMedGoogle Scholar
  33. 33.
    Percy CL, Smith MA, Linet M, Gloeckler Ries LA, Friedman DL. Lymphoma and reticuloendothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG, et.al., eds. Cancer incidence and survival among children and adolescents. United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program, 1999;35–49. Available at: http://www.acco.org/LinkClick.aspx?fileticket=CGsKkvHaH1Y%3D&tabid=670. Accessed November, 2012.
  34. 34.
    Fujita N, Kobayashi R, Takimoto T, Nakagawa A, Ueda K, Horibe K. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma. 2011;52(2):223–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, et al. Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children’s Cancer Study Group NHL B9604 protocol. Leuk Lymphoma. 2008;49(4):757–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Tsurusawa M, Katano N, Hirota T, Ito M, Yanase T, Asami K, et al. Studies of childhood non-Hodgkin’s lymphoma-treatment results with the CCLSG NHL 960 protocol. Children’s Cancer and Leukemia Study Group (CCLSG). Rinsho Ketsueki. 1998;39(11):1092–8.PubMedGoogle Scholar
  37. 37.
    Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–306.PubMedGoogle Scholar
  38. 38.
    Bhatia S, Nesbit ME Jr, Egeler RM, Buckley JD, Mertens A, Robison LL. Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr. 1997;130(5):774–84.PubMedCrossRefGoogle Scholar
  39. 39.
    Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107(3):613–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58–65.PubMedCrossRefGoogle Scholar
  41. 41.
    Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Kikuchi A, Hasegawa D, Ohtsuka Y, Hamamoto K, Kojima S, Okamura J, et al. Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study. Br J Haematol. 2012;158(5):657–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Hasegawa D, Manabe A, Yagasaki H, Ohtsuka Y, Inoue M, Kikuchi A, et al. Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99). Pediatr Blood Cancer. 2009;53(6):1011–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Yoshida N, Hirabayashi S, Watanabe S, Zaike Y, Tsuchida M, Yoshimi A, et al. Prognosis of 75 patients with juvenile myelomonocytic leukemia: prospective study by MDS committee in the Japanese Society of Pediatric Hematology. Rinsho Ketsueki. 2011;52(12):1853–8.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Keizo Horibe
    • 1
    Email author
  • Akiko M. Saito
    • 1
  • Tetsuya Takimoto
    • 2
  • Masahiro Tsuchida
    • 3
  • Atsushi Manabe
    • 4
  • Midori Shima
    • 5
  • Akira Ohara
    • 6
  • Shuki Mizutani
    • 7
  1. 1.Clinical Research CenterNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  2. 2.Clinical Research CenterNational Center for Child Health and DevelopmentTokyoJapan
  3. 3.Ibaraki Children’s HospitalIbarakiJapan
  4. 4.Department of PediatricsSt. Luke’s International HospitalTokyoJapan
  5. 5.Department of PediatricsNara Medical UniversityNaraJapan
  6. 6.Toho University Omori Medical CenterTokyoJapan
  7. 7.Department of PediatricsTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations